Monopar Therapeutics (NASDAQ:MNPR) Stock Price Up 4.8% – Time to Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price traded up 4.8% on Thursday . The company traded as high as $84.92 and last traded at $86.58. 121,534 shares traded hands during trading, an increase of 126% from the average session volume of 53,764 shares. The stock had previously closed at $82.58.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Wednesday, October 8th. Chardan Capital boosted their price target on shares of Monopar Therapeutics from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Sunday, November 9th. Barclays set a $125.00 price objective on shares of Monopar Therapeutics and gave the stock an “overweight” rating in a research note on Monday, October 13th. HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the company a “buy” rating in a research report on Monday, September 29th. Finally, Leerink Partners assumed coverage on Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics presently has a consensus rating of “Buy” and an average target price of $106.20.

Monopar Therapeutics Stock Down 10.4%

The stock’s fifty day moving average price is $78.12 and its 200-day moving average price is $51.42.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, analysts predict that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Insider Buying and Selling at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the sale, the insider owned 272,026 shares in the company, valued at approximately $17,303,573.86. This represents a 66.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MNPR. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets lifted its position in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics during the second quarter worth approximately $34,000. AlphaQuest LLC acquired a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $44,000. Finally, JPMorgan Chase & Co. grew its position in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.